董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew Einhorn | 男 | Independent Director | 66 | 32.47万美元 | 未持股 | 2026-09-29 |
| Ezra Friedberg | 男 | Independent Director | 56 | 89.68万美元 | 21.15 | 2026-09-29 |
| Scott Plesha | 男 | Chief Executive Officer,Director and President | 61 | 415.32万美元 | 11.29 | 2026-09-29 |
| Todd Davis | 男 | Independent Director | 65 | 89.68万美元 | 8.81 | 2026-09-29 |
| Richard Malamut | 男 | Independent Director | 66 | 89.68万美元 | 3.68 | 2026-09-29 |
| Richard Baxter | 男 | Independent Director | 62 | 85.68万美元 | 2.58 | 2026-09-29 |
| Matthew Pauls | 男 | Independent Director | 55 | 112.82万美元 | 5.76 | 2026-09-29 |
| Peter Greenleaf | 男 | Chairman of the Board and Independent Director | 56 | 113.32万美元 | 6.72 | 2026-09-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott Plesha | 男 | Chief Executive Officer,Director and President | 61 | 415.32万美元 | 11.29 | 2026-09-29 |
| John M. Gay | 男 | Chief Financial Officer, Secretary and Treasurer | 49 | 未披露 | 未持股 | 2026-09-29 |
| Sai Rangarao | 男 | Chief Commercial Officer | 42 | 172.34万美元 | 4.12 | 2026-09-29 |
| John M. Gay | 男 | Chief Financial Officer, Secretary and Treasurer | 50 | 未披露 | 未持股 | 2026-09-29 |
董事简历
中英对照 | 中文 | 英文- Andrew Einhorn
-
Andrew Einhorn自2014年3月加入公司担任财务总监。在那之前，担任公司发展执行副总裁（2013年5月）。Einhorn先生在制药行业有着10多年的经验。在加入公司之前，Einhorn先生担任Myos 公司（Myos Corporation NASDAQ： MYOSD）的财务总监（2012年10月-2013年2月）；也是一名独立顾问（2013年3-5月和2012年1月-2012年10月）；也是Oceana Therapeutics股份有限公司（Oceana Therapeutics, Inc.）的联合创始人、执行副总裁和财务总监（2008年5月-2012年1月）。先前，Einhorn先生是Esprit Pharma股份有限公司（Esprit Pharma, Inc.，2005年6月-2007年10月）和ESP Pharma股份有限公司（ESP Pharma, Inc.，2003年4月-2005年3月）的联合创始人和财务总监。1983-2003年Einhorn先生是Credit Lyonnais Securities、PNC Capital Markets、Chase Securities股份有限公司（Chase Securities, Inc.）、Bankers Trust公司（Bankers Trust Company）和Chase Manhattan 银行（Chase Manhattan Bank）的投资银行家。Einhorn先生是新泽西州（State of New Jersey）一名注册会计师，拥有美国大学（American University）财务和会计学士学位。
Andrew Einhorn has served as a member of Pelthos Therapeutics Inc.'s Board since December 2025. Mr. Einhorn is a consultant for Danforth Advisors where he has served as a fractional CFO and strategic advisor to public and private commercial and clinical stage biotechnology companies in infectious disease, neurodegenerative disease, rare disease, oncology, ocular gene therapy and gastrointestinal therapeutic areas. Previously, from September 2017 – May 2022 he served as Chief Financial Officer of RVL Pharmaceuticals plc (formerly Osmotica Pharmaceuticals plc) a specialty pharmaceutical company which went public in October 2018. From May 2013 to March 2017, Mr. Einhorn served as the Chief Financial Officer and Executive Vice President of Corporate Development of Edge Therapeutics, Inc., a clinical stage biotechnology company that completed its IPO in September 2015. Prior to Edge, he was a co founder and Chief Financial Officer of three specialty pharmaceutical and therapeutics companies: Oceana Therapeutics, Inc., Esprit Pharma, Inc. and ESP Pharma, Inc. From 1983 to 2003, Mr. Einhorn was an investment banker with Credit Lyonnais Securities, PNC Capital Markets, Chase Securities, Inc., Bankers Trust Company and the Chase Manhattan Bank. Previously, Mr. Einhorn was a senior accountant at Touche Ross & Co. Mr. Einhorn was a Certified Public Accountant in the State of New Jersey and holds a B.S. in Finance and Accounting from The American University. Mr. Einhorn currently serves as a venture advisor to the Israel Biotechnology Fund. - Andrew Einhorn自2014年3月加入公司担任财务总监。在那之前，担任公司发展执行副总裁（2013年5月）。Einhorn先生在制药行业有着10多年的经验。在加入公司之前，Einhorn先生担任Myos 公司（Myos Corporation NASDAQ： MYOSD）的财务总监（2012年10月-2013年2月）；也是一名独立顾问（2013年3-5月和2012年1月-2012年10月）；也是Oceana Therapeutics股份有限公司（Oceana Therapeutics, Inc.）的联合创始人、执行副总裁和财务总监（2008年5月-2012年1月）。先前，Einhorn先生是Esprit Pharma股份有限公司（Esprit Pharma, Inc.，2005年6月-2007年10月）和ESP Pharma股份有限公司（ESP Pharma, Inc.，2003年4月-2005年3月）的联合创始人和财务总监。1983-2003年Einhorn先生是Credit Lyonnais Securities、PNC Capital Markets、Chase Securities股份有限公司（Chase Securities, Inc.）、Bankers Trust公司（Bankers Trust Company）和Chase Manhattan 银行（Chase Manhattan Bank）的投资银行家。Einhorn先生是新泽西州（State of New Jersey）一名注册会计师，拥有美国大学（American University）财务和会计学士学位。
- Andrew Einhorn has served as a member of Pelthos Therapeutics Inc.'s Board since December 2025. Mr. Einhorn is a consultant for Danforth Advisors where he has served as a fractional CFO and strategic advisor to public and private commercial and clinical stage biotechnology companies in infectious disease, neurodegenerative disease, rare disease, oncology, ocular gene therapy and gastrointestinal therapeutic areas. Previously, from September 2017 – May 2022 he served as Chief Financial Officer of RVL Pharmaceuticals plc (formerly Osmotica Pharmaceuticals plc) a specialty pharmaceutical company which went public in October 2018. From May 2013 to March 2017, Mr. Einhorn served as the Chief Financial Officer and Executive Vice President of Corporate Development of Edge Therapeutics, Inc., a clinical stage biotechnology company that completed its IPO in September 2015. Prior to Edge, he was a co founder and Chief Financial Officer of three specialty pharmaceutical and therapeutics companies: Oceana Therapeutics, Inc., Esprit Pharma, Inc. and ESP Pharma, Inc. From 1983 to 2003, Mr. Einhorn was an investment banker with Credit Lyonnais Securities, PNC Capital Markets, Chase Securities, Inc., Bankers Trust Company and the Chase Manhattan Bank. Previously, Mr. Einhorn was a senior accountant at Touche Ross & Co. Mr. Einhorn was a Certified Public Accountant in the State of New Jersey and holds a B.S. in Finance and Accounting from The American University. Mr. Einhorn currently serves as a venture advisor to the Israel Biotechnology Fund.
- Ezra Friedberg
-
Ezra Friedberg，2016年6月以来，他担任KaloBios制药的董事会成员。2012年以来，他担任Multiplier Capital（他成立的基金，专注于贷款机会赞助支持成长型企业）的普通合伙人。他是该基金的信贷委员会成员。此外，他拥有并经营着其他金融服务业务。2003年以来，他担任Key Recovery Group（一个私募股权投资公司）和the PUN Companies（不良债务买家）的创会人和经理。他获得Ner Israel Rabbinical College的犹太教法典的法律学士学位和 Johns Hopkins University的管理科学硕士学位。
Ezra Friedberg has served as a member of Pelthos Therapeutics Inc.'s Board since May 2021. Mr. Friedberg is a seasoned investor with more than twenty years of investing experience in both public and private companies. He invests actively in the biotech space and has served on the board of directors of Humanigen (HGEN), a clinical stage biopharmaceutical company which develops monoclonal antibodies. Mr. Friedberg is a graduate of Johns Hopkins University.He received a Bachelor of Laws from Ner Israel Rabbinical College and a Master of Management Science from Johns Hopkins University. - Ezra Friedberg，2016年6月以来，他担任KaloBios制药的董事会成员。2012年以来，他担任Multiplier Capital（他成立的基金，专注于贷款机会赞助支持成长型企业）的普通合伙人。他是该基金的信贷委员会成员。此外，他拥有并经营着其他金融服务业务。2003年以来，他担任Key Recovery Group（一个私募股权投资公司）和the PUN Companies（不良债务买家）的创会人和经理。他获得Ner Israel Rabbinical College的犹太教法典的法律学士学位和 Johns Hopkins University的管理科学硕士学位。
- Ezra Friedberg has served as a member of Pelthos Therapeutics Inc.'s Board since May 2021. Mr. Friedberg is a seasoned investor with more than twenty years of investing experience in both public and private companies. He invests actively in the biotech space and has served on the board of directors of Humanigen (HGEN), a clinical stage biopharmaceutical company which develops monoclonal antibodies. Mr. Friedberg is a graduate of Johns Hopkins University.He received a Bachelor of Laws from Ner Israel Rabbinical College and a Master of Management Science from Johns Hopkins University.
- Scott Plesha
-
Scott Plesha自2025年7月起担任Pelthos Therapeutics Inc.的首席执行官和总裁，并担任Pelthos Therapeutics Inc.的董事会成员，Plesha先生于2023年11月至2025年7月担任LNHC的首席执行官。在加入LNHC之前，Plesha先生曾于2018年1月在BioDelivery Sciences（BDSI）担任总裁兼首席商务官，该公司是一家商业阶段的专业制药公司，致力于治疗慢性病患者，直至2022年被Collegium制药收购。Plesha先生于2015年8月加入BioDelivery Sciences，担任销售高级副总裁，并于2015年12月承担领导营销部门的额外职责。此前曾担任柳药医疗胃肠销售高级副总裁。在加入Salix之前，Plesha先生是Oclassen Dermatologics（沃森实验室的一个部门）的区域销售经理，并在Solvay Pharmaceuticals担任越来越重要的商业职务。
Scott Plesha has served as Pelthos Therapeutics Inc.'s Chief Executive Officer and President and as a member of Pelthos Therapeutics Inc.'s Board since July 2025, and Mr. Plesha served as the Chief Executive Officer of LNHC from November 2023 to July 2025. Prior to joining LNHC, Mr. Plesha served as the President and Chief Commercial Officer at BioDelivery Sciences (BDSI), a commercial stage specialty pharmaceutical company dedicated to patients living with chronic conditions, from January 2018 until it was acquired by Collegium Pharmaceutical in 2022. Mr. Plesha joined BioDelivery Sciences in August 2015 as Senior Vice President, Sales, and assumed the additional responsibility of leading the marketing department in December 2015. He previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. Before Salix, Mr. Plesha was a Regional Sales Manager for Oclassen Dermatologics, a division of Watson Laboratories, and in commercial roles of increasing responsibility at Solvay Pharmaceuticals. - Scott Plesha自2025年7月起担任Pelthos Therapeutics Inc.的首席执行官和总裁，并担任Pelthos Therapeutics Inc.的董事会成员，Plesha先生于2023年11月至2025年7月担任LNHC的首席执行官。在加入LNHC之前，Plesha先生曾于2018年1月在BioDelivery Sciences（BDSI）担任总裁兼首席商务官，该公司是一家商业阶段的专业制药公司，致力于治疗慢性病患者，直至2022年被Collegium制药收购。Plesha先生于2015年8月加入BioDelivery Sciences，担任销售高级副总裁，并于2015年12月承担领导营销部门的额外职责。此前曾担任柳药医疗胃肠销售高级副总裁。在加入Salix之前，Plesha先生是Oclassen Dermatologics（沃森实验室的一个部门）的区域销售经理，并在Solvay Pharmaceuticals担任越来越重要的商业职务。
- Scott Plesha has served as Pelthos Therapeutics Inc.'s Chief Executive Officer and President and as a member of Pelthos Therapeutics Inc.'s Board since July 2025, and Mr. Plesha served as the Chief Executive Officer of LNHC from November 2023 to July 2025. Prior to joining LNHC, Mr. Plesha served as the President and Chief Commercial Officer at BioDelivery Sciences (BDSI), a commercial stage specialty pharmaceutical company dedicated to patients living with chronic conditions, from January 2018 until it was acquired by Collegium Pharmaceutical in 2022. Mr. Plesha joined BioDelivery Sciences in August 2015 as Senior Vice President, Sales, and assumed the additional responsibility of leading the marketing department in December 2015. He previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. Before Salix, Mr. Plesha was a Regional Sales Manager for Oclassen Dermatologics, a division of Watson Laboratories, and in commercial roles of increasing responsibility at Solvay Pharmaceuticals.
- Todd Davis
-
Todd Davis自2023年1月起担任Pelthos Therapeutics Inc.董事会成员。自2022年12月起担任Ligand的首席执行官，自2007年起担任Ligand董事会成员。他是创始人，自2018年起担任特殊机会投资公司RoyaltyRx Capital，LLC的管理合伙人。自2019年11月起，他还担任医药控股公司Benuvia Holdings，LLC的董事长兼首席执行官。从2006年到2018年，戴维斯先生是全球医疗保健投资公司HealthCare Royalty Partners的创始人和管理合伙人。从2004年到2006年，戴维斯先生是Paul Capital Partners的合伙人，在那里他作为版税管理委员会成员共同管理其版税投资。2001年至2004年，他在Apax Partners担任负责生物制药增长股权投资的合伙人。Davis先生的商业生涯始于雅培的销售部门，在那里他担任过几个责任越来越大的商业职务。随后，他在Elan Pharmaceuticals担任一般管理、业务发展和许可职务。戴维斯先生是一名海军老兵，曾获得美国海军学院的学士学位和哈佛商学院的工商管理硕士学位。除了在Ligand担任董事会职务外，他目前自2024年起担任Palvella Therapeutics Inc.的董事会成员，并于20212023年期间担任Vaxart，Inc.的董事会成员，于2018年5月至2022年3月期间担任BDSI的董事会成员。他还是哈佛商学院医疗保健校友协会的前董事会成员。
Todd Davis has served as a member of Pelthos Therapeutics Inc.'s Board since January 2023. He is the Chief Executive Officer of Ligand since December 2022 and is a member of the Ligand board of directors since 2007. He is the founder and has served as the managing partner of RoyaltyRx Capital, LLC, a special opportunities investment firm, since 2018. Since November 2019, he has also served as Chairman and CEO of Benuvia Holdings, LLC, a pharmaceutical holding company. From 2006 to 2018, Mr. Davis was a founder and Managing Partner of HealthCare Royalty Partners, a global healthcare investment firm. From 2004 to 2006, Mr. Davis was a partner at Paul Capital Partners, where he co managed its royalty investments as a member of the Royalty Management Committee. From 2001 to 2004, he served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Mr. Davis began his business career in sales at Abbott Laboratories where he held several commercial roles of increasing responsibility. He subsequently held general management, business development, and licensing roles at Elan Pharmaceuticals. Mr. Davis is a navy veteran and received a B.S. from the U.S. Naval Academy and an M.B.A. from the Harvard Business School. In addition to his board position at Ligand, he currently serves on the board of directors of Palvella Therapeutics Inc. since 2024 and served on the board of directors for Vaxart, Inc. from 2021 2023 and BDSI from May 2018 through March 2022. He is also a former board member of the Harvard Business School Healthcare Alumni Association. - Todd Davis自2023年1月起担任Pelthos Therapeutics Inc.董事会成员。自2022年12月起担任Ligand的首席执行官，自2007年起担任Ligand董事会成员。他是创始人，自2018年起担任特殊机会投资公司RoyaltyRx Capital，LLC的管理合伙人。自2019年11月起，他还担任医药控股公司Benuvia Holdings，LLC的董事长兼首席执行官。从2006年到2018年，戴维斯先生是全球医疗保健投资公司HealthCare Royalty Partners的创始人和管理合伙人。从2004年到2006年，戴维斯先生是Paul Capital Partners的合伙人，在那里他作为版税管理委员会成员共同管理其版税投资。2001年至2004年，他在Apax Partners担任负责生物制药增长股权投资的合伙人。Davis先生的商业生涯始于雅培的销售部门，在那里他担任过几个责任越来越大的商业职务。随后，他在Elan Pharmaceuticals担任一般管理、业务发展和许可职务。戴维斯先生是一名海军老兵，曾获得美国海军学院的学士学位和哈佛商学院的工商管理硕士学位。除了在Ligand担任董事会职务外，他目前自2024年起担任Palvella Therapeutics Inc.的董事会成员，并于20212023年期间担任Vaxart，Inc.的董事会成员，于2018年5月至2022年3月期间担任BDSI的董事会成员。他还是哈佛商学院医疗保健校友协会的前董事会成员。
- Todd Davis has served as a member of Pelthos Therapeutics Inc.'s Board since January 2023. He is the Chief Executive Officer of Ligand since December 2022 and is a member of the Ligand board of directors since 2007. He is the founder and has served as the managing partner of RoyaltyRx Capital, LLC, a special opportunities investment firm, since 2018. Since November 2019, he has also served as Chairman and CEO of Benuvia Holdings, LLC, a pharmaceutical holding company. From 2006 to 2018, Mr. Davis was a founder and Managing Partner of HealthCare Royalty Partners, a global healthcare investment firm. From 2004 to 2006, Mr. Davis was a partner at Paul Capital Partners, where he co managed its royalty investments as a member of the Royalty Management Committee. From 2001 to 2004, he served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Mr. Davis began his business career in sales at Abbott Laboratories where he held several commercial roles of increasing responsibility. He subsequently held general management, business development, and licensing roles at Elan Pharmaceuticals. Mr. Davis is a navy veteran and received a B.S. from the U.S. Naval Academy and an M.B.A. from the Harvard Business School. In addition to his board position at Ligand, he currently serves on the board of directors of Palvella Therapeutics Inc. since 2024 and served on the board of directors for Vaxart, Inc. from 2021 2023 and BDSI from May 2018 through March 2022. He is also a former board member of the Harvard Business School Healthcare Alumni Association.
- Richard Malamut
-
Richard Malamut自2023年1月起担任Pelthos Therapeutics Inc.董事会成员。Malamut博士目前担任MedinCell Inc.的首席医疗官。他最近于2019年4月至2022年5月担任Collegium Pharmaceuticals的首席医疗官和执行副总裁，并于2018年至2019年期间担任Braeburn Pharmaceuticals，Inc.的首席医疗官，负责公司的医疗事务、非临床和临床开发、临床运营、研发质量保证以及药物警戒职能。在此之前，Malamut博士曾于2016年至2018年在Avanir制药担任首席医疗官，并于2013年至2016年在梯瓦制药有限公司担任全球临床开发高级副总裁，负责疼痛、神经精神病学、肿瘤学和新的治疗实体。他的经历还包括在百时美施贵宝和阿斯利康担任越来越多的角色，专注于神经病学、精神病学和镇痛领域的早期临床开发和转化医学。马拉穆特博士在费城哈内曼大学获得医学学位，并完成了神经病学住院医师和神经肌肉疾病研究金。担任董事会认证学术和临床神经科医生17年，在疼痛医学、神经肌肉疾病、自主神经疾病、神经退行性疾病等领域发表论文50余篇。
Richard Malamut has served as a member of Pelthos Therapeutics Inc.'s Board since January 2023. Dr. Malamut is currently Chief Medical Officer at MedinCell Inc. He was most recently Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals from April 2019 to May 2022 and has also served as Chief Medical Officer for Braeburn Pharmaceuticals, Inc. from 2018 to 2019 where he was responsible for the company's medical affairs, non clinical and clinical development, clinical operations, research and development quality assurance, and pharmacovigilance functions. Prior to that, Dr. Malamut had similar responsibilities as Chief Medical Officer at Avanir Pharmaceuticals from 2016 to 2018 and was Senior Vice President of Global Clinical Development at Teva Pharmaceutical Industries Ltd from 2013 to 2016 where he was responsible for Pain, Neuropsychiatry, Oncology, and New Therapeutic Entities. His experience also includes roles of increasing responsibility focusing on early clinical development and translational medicine in Neurology, Psychiatry and Analgesia at Bristol Myers Squibb and AstraZeneca. Dr. Malamut earned his medical degree from Hahnemann University in Philadelphia and completed both a residency in Neurology and a fellowship in neuromuscular disease. He worked as a board certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease, and neurodegenerative disease. - Richard Malamut自2023年1月起担任Pelthos Therapeutics Inc.董事会成员。Malamut博士目前担任MedinCell Inc.的首席医疗官。他最近于2019年4月至2022年5月担任Collegium Pharmaceuticals的首席医疗官和执行副总裁，并于2018年至2019年期间担任Braeburn Pharmaceuticals，Inc.的首席医疗官，负责公司的医疗事务、非临床和临床开发、临床运营、研发质量保证以及药物警戒职能。在此之前，Malamut博士曾于2016年至2018年在Avanir制药担任首席医疗官，并于2013年至2016年在梯瓦制药有限公司担任全球临床开发高级副总裁，负责疼痛、神经精神病学、肿瘤学和新的治疗实体。他的经历还包括在百时美施贵宝和阿斯利康担任越来越多的角色，专注于神经病学、精神病学和镇痛领域的早期临床开发和转化医学。马拉穆特博士在费城哈内曼大学获得医学学位，并完成了神经病学住院医师和神经肌肉疾病研究金。担任董事会认证学术和临床神经科医生17年，在疼痛医学、神经肌肉疾病、自主神经疾病、神经退行性疾病等领域发表论文50余篇。
- Richard Malamut has served as a member of Pelthos Therapeutics Inc.'s Board since January 2023. Dr. Malamut is currently Chief Medical Officer at MedinCell Inc. He was most recently Chief Medical Officer and Executive Vice President at Collegium Pharmaceuticals from April 2019 to May 2022 and has also served as Chief Medical Officer for Braeburn Pharmaceuticals, Inc. from 2018 to 2019 where he was responsible for the company's medical affairs, non clinical and clinical development, clinical operations, research and development quality assurance, and pharmacovigilance functions. Prior to that, Dr. Malamut had similar responsibilities as Chief Medical Officer at Avanir Pharmaceuticals from 2016 to 2018 and was Senior Vice President of Global Clinical Development at Teva Pharmaceutical Industries Ltd from 2013 to 2016 where he was responsible for Pain, Neuropsychiatry, Oncology, and New Therapeutic Entities. His experience also includes roles of increasing responsibility focusing on early clinical development and translational medicine in Neurology, Psychiatry and Analgesia at Bristol Myers Squibb and AstraZeneca. Dr. Malamut earned his medical degree from Hahnemann University in Philadelphia and completed both a residency in Neurology and a fellowship in neuromuscular disease. He worked as a board certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease, and neurodegenerative disease.
- Richard Baxter
-
Richard Baxter自2025年7月起担任Pelthos Therapeutics Inc.董事会成员。他目前担任投资运营高级副总裁，自2024年起担任Ligand投资委员会成员。从2020年到2024年，Baxter先生担任Birch Lake Partners的董事总经理和合伙人，目前是Birch Lake顾问委员会的成员。Baxter先生是Fortress投资吊桥特别机会基金的医疗保健集团的联合创始人，并于2004年至2010年担任Fortress投资的董事总经理。他还曾于2013年至2017年在Hayfin Capital Management LLP担任董事总经理和医疗团队联席主管。在开始投资生涯之前，他曾在制药行业担任高级职务，担任PathoGensis Corp.、ViroPharma Inc.的销售、营销和业务发展主管，以及SmithKline Beecham的营销领导。他获得了普林斯顿大学的A.B.（优等生）和哈佛商学院的MBA学位。
Richard Baxter has served as a member of Pelthos Therapeutics Inc.'s Board since July 2025. He is currently the Senior Vice President of Investment Operations and a member of the Investment Committee at Ligand since 2024. From 2020 2024, Mr. Baxter was a Managing Director and Partner of Birch Lake Partners and is currently a member of Birch Lake's Advisory Board. Mr. Baxter is a co founder of the healthcare group for the Drawbridge Special Opportunities Fund at Fortress Investment Group and was a Managing Director at Fortress Investment Group from 2004 to 2010. He also previously served as a Managing Director and co head of the healthcare team at Hayfin Capital Management LLP from 2013 to 2017. Before starting his investment career, he held senior roles in the pharmaceutical industry as Head of Sales, Marketing, and Business Development at PathoGensis Corp., ViroPharma Inc., and Marketing leadership at SmithKline Beecham. He earned an A.B. (cum laude) from Princeton University and an MBA from Harvard Business School. - Richard Baxter自2025年7月起担任Pelthos Therapeutics Inc.董事会成员。他目前担任投资运营高级副总裁，自2024年起担任Ligand投资委员会成员。从2020年到2024年，Baxter先生担任Birch Lake Partners的董事总经理和合伙人，目前是Birch Lake顾问委员会的成员。Baxter先生是Fortress投资吊桥特别机会基金的医疗保健集团的联合创始人，并于2004年至2010年担任Fortress投资的董事总经理。他还曾于2013年至2017年在Hayfin Capital Management LLP担任董事总经理和医疗团队联席主管。在开始投资生涯之前，他曾在制药行业担任高级职务，担任PathoGensis Corp.、ViroPharma Inc.的销售、营销和业务发展主管，以及SmithKline Beecham的营销领导。他获得了普林斯顿大学的A.B.（优等生）和哈佛商学院的MBA学位。
- Richard Baxter has served as a member of Pelthos Therapeutics Inc.'s Board since July 2025. He is currently the Senior Vice President of Investment Operations and a member of the Investment Committee at Ligand since 2024. From 2020 2024, Mr. Baxter was a Managing Director and Partner of Birch Lake Partners and is currently a member of Birch Lake's Advisory Board. Mr. Baxter is a co founder of the healthcare group for the Drawbridge Special Opportunities Fund at Fortress Investment Group and was a Managing Director at Fortress Investment Group from 2004 to 2010. He also previously served as a Managing Director and co head of the healthcare team at Hayfin Capital Management LLP from 2013 to 2017. Before starting his investment career, he held senior roles in the pharmaceutical industry as Head of Sales, Marketing, and Business Development at PathoGensis Corp., ViroPharma Inc., and Marketing leadership at SmithKline Beecham. He earned an A.B. (cum laude) from Princeton University and an MBA from Harvard Business School.
- Matthew Pauls
-
Matthew Pauls，于2013年4月1日加入本公司，担任首席商务官。他拥有超过20年的制药业经验，包括在一些领先的医药公司的全球营销、美国营销、总务、销售管理、报销、新产品发布和商业运营等高层领导职务。在2007年7月-2013年5月期间，他曾在全球生物制药公司- Shire PLC LSE： SHP的美国（U.S。）子公司- Shire Pharmaceuticals股份有限公司的数个部门担任若干高级商务职位。最近，他曾在Shire Regenerative Medicine股份有限公司担任高级副总裁、全球商业运营主管。在那之前，他曾在Shire Specialty Pharmaceuticals、 Shire Regenerative Medicine担任副总裁、全球商业运营主管；在Shire Specialty Pharmaceuticals的行为健康业务部担任副总裁及产品总经理；在Shire Specialty Pharmaceuticals的ADHD业务部担任副总裁及产品总经理；以及在Shire Specialty PharmaceuticalsADHD业务部担任总经理。在2005-2007年期间，他曾在Bristol-Myers Squibb公司担任高层管理职位。在1997-2005年期间，他曾在Johnson & Johnson股份有限公司担任若干职位。他是在密歇根（Michigan）州立大学法学院获得他的法学博士学位，以及在中密歇根大学（Central Michigan University）获得他的工商管理学硕士学位的。
Matthew Pauls has served as a member of Pelthos Therapeutics Inc.'s Board since June 2025. Since 2020, Mr. Pauls has served as Chair of the board of directors and Chief Executive Officer of Savara Inc., a publicly traded clinical stage biopharmaceutical company focused on rare respiratory diseases. He also serves on the boards of directors of Palvella Therapeutics, a publicly traded clinical stage company focused on novel therapies to treat patients living with serious rare skin and vascular malformations, and Atsena Therapeutics, a gene therapy company focused on developing treatments for inherited retinal diseases that cause blindness. From 2020 to 2026, he served on the board of directors of Amplo Biotechnology, a private gene therapy company focused on rare neuromuscular disorders, and from 2023 to 2026, he served on the board of directors of Soleno Therapeutics, a publicly traded rare disease biopharmaceutical company, where he served as Lead Independent Director from 2024 until Soleno was acquired by Neurocrine Biosciences in August 2026. From 2014 to 2019, Mr. Pauls was President and Chief Executive Officer and a member of the board of directors of Strongbridge Biopharma plc., a publicly traded rare disease focused biopharmaceutical company that he took public via IPO on the NASDAQ. Prior to 2014, he served as Chief Commercial Officer of Insmed, Inc., where he led both the global Commercial and Technical Operations organizations. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations, and earlier in his career held senior commercial leadership positions at Bristol Myers Squibb and Johnson & Johnson. In addition to his other Board positions, Mr. Pauls has also served as Chair of the Board of Directors of Mast Therapeutics and was a member of the Board of Directors of Zyla Life Sciences, both publicly traded biopharma companies. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law. - Matthew Pauls，于2013年4月1日加入本公司，担任首席商务官。他拥有超过20年的制药业经验，包括在一些领先的医药公司的全球营销、美国营销、总务、销售管理、报销、新产品发布和商业运营等高层领导职务。在2007年7月-2013年5月期间，他曾在全球生物制药公司- Shire PLC LSE： SHP的美国（U.S。）子公司- Shire Pharmaceuticals股份有限公司的数个部门担任若干高级商务职位。最近，他曾在Shire Regenerative Medicine股份有限公司担任高级副总裁、全球商业运营主管。在那之前，他曾在Shire Specialty Pharmaceuticals、 Shire Regenerative Medicine担任副总裁、全球商业运营主管；在Shire Specialty Pharmaceuticals的行为健康业务部担任副总裁及产品总经理；在Shire Specialty Pharmaceuticals的ADHD业务部担任副总裁及产品总经理；以及在Shire Specialty PharmaceuticalsADHD业务部担任总经理。在2005-2007年期间，他曾在Bristol-Myers Squibb公司担任高层管理职位。在1997-2005年期间，他曾在Johnson & Johnson股份有限公司担任若干职位。他是在密歇根（Michigan）州立大学法学院获得他的法学博士学位，以及在中密歇根大学（Central Michigan University）获得他的工商管理学硕士学位的。
- Matthew Pauls has served as a member of Pelthos Therapeutics Inc.'s Board since June 2025. Since 2020, Mr. Pauls has served as Chair of the board of directors and Chief Executive Officer of Savara Inc., a publicly traded clinical stage biopharmaceutical company focused on rare respiratory diseases. He also serves on the boards of directors of Palvella Therapeutics, a publicly traded clinical stage company focused on novel therapies to treat patients living with serious rare skin and vascular malformations, and Atsena Therapeutics, a gene therapy company focused on developing treatments for inherited retinal diseases that cause blindness. From 2020 to 2026, he served on the board of directors of Amplo Biotechnology, a private gene therapy company focused on rare neuromuscular disorders, and from 2023 to 2026, he served on the board of directors of Soleno Therapeutics, a publicly traded rare disease biopharmaceutical company, where he served as Lead Independent Director from 2024 until Soleno was acquired by Neurocrine Biosciences in August 2026. From 2014 to 2019, Mr. Pauls was President and Chief Executive Officer and a member of the board of directors of Strongbridge Biopharma plc., a publicly traded rare disease focused biopharmaceutical company that he took public via IPO on the NASDAQ. Prior to 2014, he served as Chief Commercial Officer of Insmed, Inc., where he led both the global Commercial and Technical Operations organizations. Prior to Insmed, Mr. Pauls worked at Shire Pharmaceuticals, most recently as Senior Vice President, Head of Global Commercial Operations, and earlier in his career held senior commercial leadership positions at Bristol Myers Squibb and Johnson & Johnson. In addition to his other Board positions, Mr. Pauls has also served as Chair of the Board of Directors of Mast Therapeutics and was a member of the Board of Directors of Zyla Life Sciences, both publicly traded biopharma companies. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.
- Peter Greenleaf
-
Peter Greenleaf于2016年1月成为Sucampo Pharmaceuticals, Inc.的主席，自2014年3月起担任Sucampo Pharmaceuticals, Inc.的首席执行官和董事会成员。2013年6月至2014年2月，Greenleaf先生担任再生医学公司Historogenics Corporation的首席执行官和董事会成员。2006年至2013年，Greenleaf先生受雇于Medimune LLC，这是阿斯利康的全球生物制剂部门，他最近在阿斯利康担任总裁。2010年1月至2013年6月，Greenleaf先生还担任Medimune Ventures的总裁。Medimune Ventures是阿斯利康集团旗下的一家全资风险投资基金。在担任Medimune总裁之前，Greenleaf先生是Medimune的首席商务官，负责其商业、公司发展和战略职能。Greenleaf先生是Mast Therapeutics，Inc.董事会成员。Mast Therapeutics，Inc.是一家临床阶段的生物制药公司，开发镰状细胞病、心力衰竭和中风的新疗法；Mirna Therapeutics是一家临床阶段的生物制药公司，开发广泛的基于microRNA的肿瘤疗法。Greenleaf先生目前担任Maryland Venture Fund Authority，其愿景是监督InvestMaryland的实施。InvestMaryland是一家公私合作企业，旨在刺激该州的风险资本投资。Greenleaf先生还是美国PhRMA和生物技术产业组织（BIO）药物研究和制造商董事会成员，他在新兴公司部门和健康部门的董事会任职。Greenleaf先生在西康涅狄格州立大学获得学士学位，在圣约瑟夫大学获得工商管理硕士学位。
Peter Greenleaf has served as the Chairman of Pelthos Therapeutics Inc.'s Board since July 2025. From April 2019 to March 2026, he served as the Chief Executive Officer and member of the board of directors of Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. From March 2018 to April 2019, he served as the CEO of Cerecor Pharmaceuticals, Inc. (now Avalo Therapeutics, Inc.). From March 2014 to February 2018, Mr. Greenleaf served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. Sucampo was focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide and was sold in February 2018 to UK pharmaceutical company, Mallinckrodt PLC. From June 2013 to March 2014, he served as CEO and a member of the board of directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, he also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of MedImmune, Mr. Greenleaf was Senior Vice President, Commercial Operations of the company, responsible for its commercial, corporate development, and strategy functions. He has also held senior commercial roles at Centocor, Inc. (now Janssen Biotechnology, Johnson & Johnson) from 1998 to 2006 and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf previously partnered with Governor Martin O'Malley to chair the Maryland Venture Fund Authority, whose vision was to oversee the implementation of Invest Maryland, a public private partnership to spur venture capital investment in the state. In addition, he has extensive public and private board experience, including as a board member for BDSI from 2018 through March 2022 and Antares Pharmaceuticals from 2019 through the second quarter of 2022 and has served in leadership roles on both BIO and PhRMA throughout the years. Mr. Greenleaf earned an MBA from St. Joseph's University and a B.S. from Western Connecticut State University. - Peter Greenleaf于2016年1月成为Sucampo Pharmaceuticals, Inc.的主席，自2014年3月起担任Sucampo Pharmaceuticals, Inc.的首席执行官和董事会成员。2013年6月至2014年2月，Greenleaf先生担任再生医学公司Historogenics Corporation的首席执行官和董事会成员。2006年至2013年，Greenleaf先生受雇于Medimune LLC，这是阿斯利康的全球生物制剂部门，他最近在阿斯利康担任总裁。2010年1月至2013年6月，Greenleaf先生还担任Medimune Ventures的总裁。Medimune Ventures是阿斯利康集团旗下的一家全资风险投资基金。在担任Medimune总裁之前，Greenleaf先生是Medimune的首席商务官，负责其商业、公司发展和战略职能。Greenleaf先生是Mast Therapeutics，Inc.董事会成员。Mast Therapeutics，Inc.是一家临床阶段的生物制药公司，开发镰状细胞病、心力衰竭和中风的新疗法；Mirna Therapeutics是一家临床阶段的生物制药公司，开发广泛的基于microRNA的肿瘤疗法。Greenleaf先生目前担任Maryland Venture Fund Authority，其愿景是监督InvestMaryland的实施。InvestMaryland是一家公私合作企业，旨在刺激该州的风险资本投资。Greenleaf先生还是美国PhRMA和生物技术产业组织（BIO）药物研究和制造商董事会成员，他在新兴公司部门和健康部门的董事会任职。Greenleaf先生在西康涅狄格州立大学获得学士学位，在圣约瑟夫大学获得工商管理硕士学位。
- Peter Greenleaf has served as the Chairman of Pelthos Therapeutics Inc.'s Board since July 2025. From April 2019 to March 2026, he served as the Chief Executive Officer and member of the board of directors of Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. From March 2018 to April 2019, he served as the CEO of Cerecor Pharmaceuticals, Inc. (now Avalo Therapeutics, Inc.). From March 2014 to February 2018, Mr. Greenleaf served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. Sucampo was focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide and was sold in February 2018 to UK pharmaceutical company, Mallinckrodt PLC. From June 2013 to March 2014, he served as CEO and a member of the board of directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, he also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group. Prior to serving as President of MedImmune, Mr. Greenleaf was Senior Vice President, Commercial Operations of the company, responsible for its commercial, corporate development, and strategy functions. He has also held senior commercial roles at Centocor, Inc. (now Janssen Biotechnology, Johnson & Johnson) from 1998 to 2006 and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf previously partnered with Governor Martin O'Malley to chair the Maryland Venture Fund Authority, whose vision was to oversee the implementation of Invest Maryland, a public private partnership to spur venture capital investment in the state. In addition, he has extensive public and private board experience, including as a board member for BDSI from 2018 through March 2022 and Antares Pharmaceuticals from 2019 through the second quarter of 2022 and has served in leadership roles on both BIO and PhRMA throughout the years. Mr. Greenleaf earned an MBA from St. Joseph's University and a B.S. from Western Connecticut State University.
高管简历
中英对照 | 中文 | 英文- Scott Plesha
Scott Plesha自2025年7月起担任Pelthos Therapeutics Inc.的首席执行官和总裁，并担任Pelthos Therapeutics Inc.的董事会成员，Plesha先生于2023年11月至2025年7月担任LNHC的首席执行官。在加入LNHC之前，Plesha先生曾于2018年1月在BioDelivery Sciences（BDSI）担任总裁兼首席商务官，该公司是一家商业阶段的专业制药公司，致力于治疗慢性病患者，直至2022年被Collegium制药收购。Plesha先生于2015年8月加入BioDelivery Sciences，担任销售高级副总裁，并于2015年12月承担领导营销部门的额外职责。此前曾担任柳药医疗胃肠销售高级副总裁。在加入Salix之前，Plesha先生是Oclassen Dermatologics（沃森实验室的一个部门）的区域销售经理，并在Solvay Pharmaceuticals担任越来越重要的商业职务。
Scott Plesha has served as Pelthos Therapeutics Inc.'s Chief Executive Officer and President and as a member of Pelthos Therapeutics Inc.'s Board since July 2025, and Mr. Plesha served as the Chief Executive Officer of LNHC from November 2023 to July 2025. Prior to joining LNHC, Mr. Plesha served as the President and Chief Commercial Officer at BioDelivery Sciences (BDSI), a commercial stage specialty pharmaceutical company dedicated to patients living with chronic conditions, from January 2018 until it was acquired by Collegium Pharmaceutical in 2022. Mr. Plesha joined BioDelivery Sciences in August 2015 as Senior Vice President, Sales, and assumed the additional responsibility of leading the marketing department in December 2015. He previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. Before Salix, Mr. Plesha was a Regional Sales Manager for Oclassen Dermatologics, a division of Watson Laboratories, and in commercial roles of increasing responsibility at Solvay Pharmaceuticals.- Scott Plesha自2025年7月起担任Pelthos Therapeutics Inc.的首席执行官和总裁，并担任Pelthos Therapeutics Inc.的董事会成员，Plesha先生于2023年11月至2025年7月担任LNHC的首席执行官。在加入LNHC之前，Plesha先生曾于2018年1月在BioDelivery Sciences（BDSI）担任总裁兼首席商务官，该公司是一家商业阶段的专业制药公司，致力于治疗慢性病患者，直至2022年被Collegium制药收购。Plesha先生于2015年8月加入BioDelivery Sciences，担任销售高级副总裁，并于2015年12月承担领导营销部门的额外职责。此前曾担任柳药医疗胃肠销售高级副总裁。在加入Salix之前，Plesha先生是Oclassen Dermatologics（沃森实验室的一个部门）的区域销售经理，并在Solvay Pharmaceuticals担任越来越重要的商业职务。
- Scott Plesha has served as Pelthos Therapeutics Inc.'s Chief Executive Officer and President and as a member of Pelthos Therapeutics Inc.'s Board since July 2025, and Mr. Plesha served as the Chief Executive Officer of LNHC from November 2023 to July 2025. Prior to joining LNHC, Mr. Plesha served as the President and Chief Commercial Officer at BioDelivery Sciences (BDSI), a commercial stage specialty pharmaceutical company dedicated to patients living with chronic conditions, from January 2018 until it was acquired by Collegium Pharmaceutical in 2022. Mr. Plesha joined BioDelivery Sciences in August 2015 as Senior Vice President, Sales, and assumed the additional responsibility of leading the marketing department in December 2015. He previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. Before Salix, Mr. Plesha was a Regional Sales Manager for Oclassen Dermatologics, a division of Watson Laboratories, and in commercial roles of increasing responsibility at Solvay Pharmaceuticals.
- John M. Gay
John M. Gay被任命为Novan, Inc.自2020年9月23日起担任首席财务官，并担任Novan, Inc.的首席财务官和公司秘书。他于2018年5月加入Novan，此前曾担任财务高级总监和公司总监（至2019年1月），以及财务和公司总监副总裁（至2020年9月23日）。从2014年5月到2018年4月，他担任Valassis Digital Corp.和MaxPoint Inc.的SEC报告董事。同性恋先生还担任Furiex制药公司控制器，Inc .）从2010年6月到2014年5月，包括从最初在纳斯达克股票交易所上市通过一项协议的执行提供由森林实验室公司的收购，Inc .)的子公司Actavis公司，这是一笔价值约11亿美元的全现金交易。加入Furiex Pharmaceuticals, Inc.之前，2000年9月至2010年5月，他曾担任Deloitte和Arthur Andersen的审计高级经理和其他职责，并不断增加。他是一名注册会计师，持有北卡罗来纳大学教堂山分校（the University of North Carolina at Chapel Hill）的经济学和历史学学士学位和会计硕士学位。
John M. Gay was appointed as Novan, Inc. Chief Financial Officer effective September 23 2020 and also serves as Novan, Inc. principal financial officer and Corporate Secretary. He joined Novan in May of 2018 and previously held the position of Senior Director of Finance and Corporate Controller through January 2019 and Vice President, Finance and Corporate Controller from January 2019 until September 23 2020. Prior to Novan, Mr. Gay held previous director positions, including Director of SEC Reporting, with Valassis Digital Corp. and MaxPoint Inc., from May 2014 to April 2018. Mr. Gay also served as Corporate Controller of Furiex Pharmaceuticals, Inc. from June 2010 to May 2014 including from its initial listing on the Nasdaq stock exchange through the execution of an agreement providing for the acquisition of the company by Forest Laboratories, Inc., a subsidiary of Actavis plc, in an all-cash transaction valued at approximately $1.1 billion. Prior to joining Furiex Pharmaceuticals, Inc., Mr. Gay served as Audit Senior Manager and in other roles of increasing responsibilities at Deloitte and Arthur Andersen from September 2000 to May 2010. Mr. Gay is a certified public accountant and holds Bachelor's degrees in Economics and History, and a Master of Accounting degree from the University of North Carolina at Chapel Hill.- John M. Gay被任命为Novan, Inc.自2020年9月23日起担任首席财务官，并担任Novan, Inc.的首席财务官和公司秘书。他于2018年5月加入Novan，此前曾担任财务高级总监和公司总监（至2019年1月），以及财务和公司总监副总裁（至2020年9月23日）。从2014年5月到2018年4月，他担任Valassis Digital Corp.和MaxPoint Inc.的SEC报告董事。同性恋先生还担任Furiex制药公司控制器，Inc .）从2010年6月到2014年5月，包括从最初在纳斯达克股票交易所上市通过一项协议的执行提供由森林实验室公司的收购，Inc .)的子公司Actavis公司，这是一笔价值约11亿美元的全现金交易。加入Furiex Pharmaceuticals, Inc.之前，2000年9月至2010年5月，他曾担任Deloitte和Arthur Andersen的审计高级经理和其他职责，并不断增加。他是一名注册会计师，持有北卡罗来纳大学教堂山分校（the University of North Carolina at Chapel Hill）的经济学和历史学学士学位和会计硕士学位。
- John M. Gay was appointed as Novan, Inc. Chief Financial Officer effective September 23 2020 and also serves as Novan, Inc. principal financial officer and Corporate Secretary. He joined Novan in May of 2018 and previously held the position of Senior Director of Finance and Corporate Controller through January 2019 and Vice President, Finance and Corporate Controller from January 2019 until September 23 2020. Prior to Novan, Mr. Gay held previous director positions, including Director of SEC Reporting, with Valassis Digital Corp. and MaxPoint Inc., from May 2014 to April 2018. Mr. Gay also served as Corporate Controller of Furiex Pharmaceuticals, Inc. from June 2010 to May 2014 including from its initial listing on the Nasdaq stock exchange through the execution of an agreement providing for the acquisition of the company by Forest Laboratories, Inc., a subsidiary of Actavis plc, in an all-cash transaction valued at approximately $1.1 billion. Prior to joining Furiex Pharmaceuticals, Inc., Mr. Gay served as Audit Senior Manager and in other roles of increasing responsibilities at Deloitte and Arthur Andersen from September 2000 to May 2010. Mr. Gay is a certified public accountant and holds Bachelor's degrees in Economics and History, and a Master of Accounting degree from the University of North Carolina at Chapel Hill.
- Sai Rangarao
Sai Rangarao自2025年7月起担任公司首席商务官。Rangarao先生于2024年3月加入公司。他有十多年领导、推出、营销大型和高度差异化医药产品的经验，包括Otezla，唯一获批适应症广泛的口服全身疗法。在加入公司之前，Rangarao先生是Collegium制药的营销副总裁，在那里他领导了全产品组合的营销和神经病学销售。他于2022年被Collegium收购时加入了collegium，此前任职于BioDelivery科学国际（BDSI）。在Rangarao先生担任BDSI营销和商业运营副总裁的领导下，公司扩大了疼痛和神经病学产品组合，并提高了公司主导产品BELBUCA的市场份额，最终导致成功出售给Collegium。在BDSI之前，他是新基医药公司皮肤科营销主管。在Celgene，Rangarao先生负责Otezla在皮肤科连续三年的商业努力，导致市场份额逐年显着增长，直到该产品以130亿美元的价格卖给了安进。他的职业生涯始于诺华制药，在全球研发、销售队伍有效性、多渠道和在线营销领域担任越来越重要的职务。Rangarao先生还担任了诺华推出COSENTYX的商业和营销组织的关键成员在美国Rangarao先生在约翰霍普金斯大学获得生物科学监管事务硕士学位，在新泽西理工学院获得MBA和硕士学位，在宾夕法尼亚印第安纳大学获得计算机科学学士学位。
Sai Rangarao has served as the Company's Chief Commercial Officer since July 2025. Mr. Rangarao joined the Company in March 2024. He has more than a decade of experience leading, launching, and marketing large and highly differentiated pharmaceutical products, including Otezla, the only approved oral systemic therapy with a broad indication. Prior to joining the Company, Mr. Rangarao was Vice President of Marketing at Collegium Pharmaceutical, where he led marketing for the full product portfolio and Neurology sales. He joined Collegium from BioDelivery Sciences International (BDSI), which was acquired by Collegium in 2022. Under Mr. Rangarao's leadership as Vice President of Marketing and Commercial Operations at BDSI, the company expanded its pain and neurology product portfolio and increased market share of the company's lead product BELBUCA, ultimately leading to the successful sale to Collegium. Before BDSI, he was Head of Dermatology Marketing at Celgene Corporation. At Celgene, Mr. Rangarao was responsible for the commercial efforts of Otezla in dermatology for three consecutive years leading to significant year over year market share growth until the product was sold to Amgen for $13 billion. He began his career at Novartis Pharmaceuticals, where he held roles of increasing responsibility across Global R&D, Sales Force Effectiveness, Multichannel, and In Line Marketing. Mr. Rangarao also served as a key member of the commercial and marketing organization at Novartis that launched COSENTYX in the U.S. Mr. Rangarao earned an M.S. in Bioscience Regulatory Affairs from The Johns Hopkins University, an MBA and M.S. from the New Jersey Institute of Technology, and a B.S. in Computer Science from Indiana University of Pennsylvania.- Sai Rangarao自2025年7月起担任公司首席商务官。Rangarao先生于2024年3月加入公司。他有十多年领导、推出、营销大型和高度差异化医药产品的经验，包括Otezla，唯一获批适应症广泛的口服全身疗法。在加入公司之前，Rangarao先生是Collegium制药的营销副总裁，在那里他领导了全产品组合的营销和神经病学销售。他于2022年被Collegium收购时加入了collegium，此前任职于BioDelivery科学国际（BDSI）。在Rangarao先生担任BDSI营销和商业运营副总裁的领导下，公司扩大了疼痛和神经病学产品组合，并提高了公司主导产品BELBUCA的市场份额，最终导致成功出售给Collegium。在BDSI之前，他是新基医药公司皮肤科营销主管。在Celgene，Rangarao先生负责Otezla在皮肤科连续三年的商业努力，导致市场份额逐年显着增长，直到该产品以130亿美元的价格卖给了安进。他的职业生涯始于诺华制药，在全球研发、销售队伍有效性、多渠道和在线营销领域担任越来越重要的职务。Rangarao先生还担任了诺华推出COSENTYX的商业和营销组织的关键成员在美国Rangarao先生在约翰霍普金斯大学获得生物科学监管事务硕士学位，在新泽西理工学院获得MBA和硕士学位，在宾夕法尼亚印第安纳大学获得计算机科学学士学位。
- Sai Rangarao has served as the Company's Chief Commercial Officer since July 2025. Mr. Rangarao joined the Company in March 2024. He has more than a decade of experience leading, launching, and marketing large and highly differentiated pharmaceutical products, including Otezla, the only approved oral systemic therapy with a broad indication. Prior to joining the Company, Mr. Rangarao was Vice President of Marketing at Collegium Pharmaceutical, where he led marketing for the full product portfolio and Neurology sales. He joined Collegium from BioDelivery Sciences International (BDSI), which was acquired by Collegium in 2022. Under Mr. Rangarao's leadership as Vice President of Marketing and Commercial Operations at BDSI, the company expanded its pain and neurology product portfolio and increased market share of the company's lead product BELBUCA, ultimately leading to the successful sale to Collegium. Before BDSI, he was Head of Dermatology Marketing at Celgene Corporation. At Celgene, Mr. Rangarao was responsible for the commercial efforts of Otezla in dermatology for three consecutive years leading to significant year over year market share growth until the product was sold to Amgen for $13 billion. He began his career at Novartis Pharmaceuticals, where he held roles of increasing responsibility across Global R&D, Sales Force Effectiveness, Multichannel, and In Line Marketing. Mr. Rangarao also served as a key member of the commercial and marketing organization at Novartis that launched COSENTYX in the U.S. Mr. Rangarao earned an M.S. in Bioscience Regulatory Affairs from The Johns Hopkins University, an MBA and M.S. from the New Jersey Institute of Technology, and a B.S. in Computer Science from Indiana University of Pennsylvania.
- John M. Gay
John M. Gay自2026年4月起担任公司首席财务官、财务主管和秘书，并于2025年7月至2026年4月担任公司财务与会计高级副总裁。在此之前，Gay先生担任LNHC的首席财务官，在收购ZELSUVMI后2023年9月。在加入LNHC之前，Gay先生于2020年9月至2023年9月担任Novan，Inc.的首席财务官和秘书，于2019年1月至2020年9月担任财务副总裁兼公司财务总监，于2018年5月至2019年1月担任财务高级总监兼公司财务总监。此前，Gay先生曾于2018年1月至2018年4月担任Valassis Digital的财务总监，并于2014年5月至2018年4月担任被Valassis Digital收购的MaxPoint Interactive，Inc.的SEC报告总监。2010年6月至2014年5月，Gay先生在Furiex制药担任公司财务总监职务。在2010年6月之前，Gay先生曾在两家注册会计师事务所担任职责不断增加的职务—— 2002年7月至2010年5月在德勤担任，2000年9月至2002年6月在安达信担任。Gay先生是北卡罗来纳州注册会计师，拥有经济学学士学位、历史学学士学位和北卡罗来纳大学教堂山分校会计学硕士学位。
John M. Gay has served as the Company's Chief Financial Officer, Treasurer and Secretary since April 2026 and as the Company's Senior Vice President, Finance & Accounting from July 2025 through April 2026. Prior to that, Mr. Gay served as Chief Financial Officer of LNHC, after the acquisition of ZELSUVMI in September 2023. Prior to joining LNHC, Mr. Gay served as Chief Financial Officer and Secretary for Novan, Inc. from September 2020 to September 2023, Vice President of Financ and Corporate Controller from January 2019 to September 2020, and Senior Director of Finance and Corporate Controller from May 2018 to January 2019. Previously, Mr. Gay served as Director of Finance for Valassis Digital from January 2018 to April 2018 and Director of SEC Reporting for MaxPoint Interactive, Inc., which was acquired by Valassis Digital, from May 2014 to April 2018. From June 2010 to May 2014, Mr. Gay held the Corporate Controller position at Furiex Pharmaceuticals, Inc. Prior to June 2010, Mr. Gay served in roles of increasing responsibility at two registered public accounting firms – Deloitte from July 2002 to May 2010 and Arthur Andersen from September 2000 to June 2002. Mr. Gay is a North Carolina certified public accountant and holds a B.A. in Economics, a B.A. in History, and a Master's in Accounting from the University of North Carolina at Chapel Hill.- John M. Gay自2026年4月起担任公司首席财务官、财务主管和秘书，并于2025年7月至2026年4月担任公司财务与会计高级副总裁。在此之前，Gay先生担任LNHC的首席财务官，在收购ZELSUVMI后2023年9月。在加入LNHC之前，Gay先生于2020年9月至2023年9月担任Novan，Inc.的首席财务官和秘书，于2019年1月至2020年9月担任财务副总裁兼公司财务总监，于2018年5月至2019年1月担任财务高级总监兼公司财务总监。此前，Gay先生曾于2018年1月至2018年4月担任Valassis Digital的财务总监，并于2014年5月至2018年4月担任被Valassis Digital收购的MaxPoint Interactive，Inc.的SEC报告总监。2010年6月至2014年5月，Gay先生在Furiex制药担任公司财务总监职务。在2010年6月之前，Gay先生曾在两家注册会计师事务所担任职责不断增加的职务—— 2002年7月至2010年5月在德勤担任，2000年9月至2002年6月在安达信担任。Gay先生是北卡罗来纳州注册会计师，拥有经济学学士学位、历史学学士学位和北卡罗来纳大学教堂山分校会计学硕士学位。
- John M. Gay has served as the Company's Chief Financial Officer, Treasurer and Secretary since April 2026 and as the Company's Senior Vice President, Finance & Accounting from July 2025 through April 2026. Prior to that, Mr. Gay served as Chief Financial Officer of LNHC, after the acquisition of ZELSUVMI in September 2023. Prior to joining LNHC, Mr. Gay served as Chief Financial Officer and Secretary for Novan, Inc. from September 2020 to September 2023, Vice President of Financ and Corporate Controller from January 2019 to September 2020, and Senior Director of Finance and Corporate Controller from May 2018 to January 2019. Previously, Mr. Gay served as Director of Finance for Valassis Digital from January 2018 to April 2018 and Director of SEC Reporting for MaxPoint Interactive, Inc., which was acquired by Valassis Digital, from May 2014 to April 2018. From June 2010 to May 2014, Mr. Gay held the Corporate Controller position at Furiex Pharmaceuticals, Inc. Prior to June 2010, Mr. Gay served in roles of increasing responsibility at two registered public accounting firms – Deloitte from July 2002 to May 2010 and Arthur Andersen from September 2000 to June 2002. Mr. Gay is a North Carolina certified public accountant and holds a B.A. in Economics, a B.A. in History, and a Master's in Accounting from the University of North Carolina at Chapel Hill.